Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944915 · ClinicalTrials.gov registry record · Phase 2
De-Escalation Therapy for Human Papillomavirus Negative Disease
A Phase 2 study of Squamous Cell Carcinoma and Human Papilloma Virus, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03944915: Completed Phase 2 study of Squamous Cell Carcinoma and Human Papilloma Virus, sponsored by University of Chicago.
NCT03944915 is a Phase 2 study of Squamous Cell Carcinoma and Human Papilloma Virus that has completed, run by University of Chicago. The registered enrollment target is 35 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03944915, a Phase 2 study of Squamous Cell Carcinoma and Human Papilloma Virus, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the subject's cancer.
Primary Outcome
DRR is 50% or greater response to induction therapy based on RECIST criteria. The objective is to intensify induction chemotherapy with the addition of an immune checkpoint inhibitor aimed at increasing the proportion of patients achieving a deep tumor response in order to subsequently allow risk-adapted definitive chemoradiotherapy in advanced stage HPV negative head and neck squamous cell cancer patients.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Nivolumab
- DRUG Paclitaxel
- RADIATION Radiation
- DRUG Hydroxyurea Pill
Study Locations (1)
Illinois
- University Of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 2 |
What the finished NCT03944915 record still lists
NCT03944915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (66% lower).
The record links to 5 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03944915 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03944915 about?
NCT03944915 is a clinical study titled "De-Escalation Therapy for Human Papillomavirus Negative Disease". This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the subject's cancer.
What is the current status of trial NCT03944915?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2019-08-26. Estimated completion is 2023-11-01.
What conditions does trial NCT03944915 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Human Papilloma Virus, Squamous Cell Carcinoma of the Head and Neck, HNSCC, HPV-Related Squamous Cell Carcinoma.
What interventions are being tested in trial NCT03944915?
The interventions under investigation include: Carboplatin (DRUG), Nivolumab (DRUG), Paclitaxel (DRUG), Radiation (RADIATION), Hydroxyurea Pill (DRUG).
Who is sponsoring clinical trial NCT03944915?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03944915 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03944915's enrollment target sits among peer trials
35 27th of 47 higher than 19 of 47 other Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI